Novartis boosts US respiratory portfolio with two COPD filings
This article was originally published in Scrip
Executive Summary
Novartis has filed new drug applications (NDAs) for two chronic obstructive pulmonary disease (COPD) drugs: QVA149 (indacaterol/glycopyrronium bromide) and NVA237 (glycopyrronium bromide).